probenecid has been researched along with Prostatic Hyperplasia in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probenecid (Prob) is a well-known FDA-approved therapy for gout owing to its uricosuric effect." | 5.91 | Probenecid ameliorates testosterone-induced benign prostatic hyperplasia: Implications of PGE-2 on ADAM-17/EGFR/ERK1/2 signaling cascade. ( Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA, 2023) |
| "Probenecid (Prob) is a well-known FDA-approved therapy for gout owing to its uricosuric effect." | 1.91 | Probenecid ameliorates testosterone-induced benign prostatic hyperplasia: Implications of PGE-2 on ADAM-17/EGFR/ERK1/2 signaling cascade. ( Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Fattah, MM | 1 |
| Abo-El Fetoh, ME | 1 |
| Afify, H | 1 |
| Ramadan, LAA | 1 |
| Mohamed, WR | 1 |
1 other study available for probenecid and Prostatic Hyperplasia
| Article | Year |
|---|---|
Probenecid ameliorates testosterone-induced benign prostatic hyperplasia: Implications of PGE-2 on ADAM-17/EGFR/ERK1/2 signaling cascade.
Topics: ADAM17 Protein; Aged; Animals; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Humans; Male; MAP Kin | 2023 |